{
  "$schema": "folio-library-document/v1",
  "id": "10665-44796",
  "title": "Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits",
  "variant": "pdf",
  "pages": 68,
  "tocSource": "inferred",
  "tocMethod": "contents",
  "toc": [
    {
      "level": 1,
      "title": "WHA 64.5 Pandemic Influenza Preparedness: sharing of influenza viruses and access to vaccine sand other benefits",
      "number": null,
      "page": 7,
      "pageLabel": "1",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-wha-645-pandemic-influenza-preparedness-sharing"
    },
    {
      "level": 1,
      "title": "Principles",
      "number": "1",
      "page": 9,
      "pageLabel": "3",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-001-1-principles"
    },
    {
      "level": 1,
      "title": "Objective",
      "number": "2",
      "page": 12,
      "pageLabel": "6",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-002-2-objective"
    },
    {
      "level": 1,
      "title": "Scope",
      "number": "3",
      "page": 13,
      "pageLabel": "7",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-003-3-scope"
    },
    {
      "level": 1,
      "title": "Definitions and use of terms",
      "number": "4",
      "page": 14,
      "pageLabel": "8",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-004-4-definitions-and-use-of-terms"
    },
    {
      "level": 2,
      "title": "Pandemic influenza preparedness biological materials or PIP biological materials",
      "number": "4.1",
      "page": 14,
      "pageLabel": "8",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-005-41-pandemic-influenza-preparedness-biological-ma"
    },
    {
      "level": 2,
      "title": "Other technical terms",
      "number": "4.2",
      "page": 14,
      "pageLabel": "8",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-006-42-other-technical-terms"
    },
    {
      "level": 2,
      "title": "Institutions, organizations and entities",
      "number": "4.3",
      "page": 16,
      "pageLabel": "10",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-007-43-institutions-organizations-and-entities"
    },
    {
      "level": 2,
      "title": "Other terms",
      "number": "4.4",
      "page": 17,
      "pageLabel": "11",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-008-44-other-terms"
    },
    {
      "level": 1,
      "title": "Pandemic influenza preparedness system for sharing of H5N1 and other influenza viruses with human pandemic potential",
      "number": "5",
      "page": 18,
      "pageLabel": "12",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-009-5-pandemic-influenza-preparedness-system-for-sha"
    },
    {
      "level": 2,
      "title": "General",
      "number": "5.1",
      "page": 18,
      "pageLabel": "12",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-010-51-general"
    },
    {
      "level": 2,
      "title": "Genetic sequence data",
      "number": "5.2",
      "page": 18,
      "pageLabel": "12",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-011-52-genetic-sequence-data"
    },
    {
      "level": 2,
      "title": "Traceability and reporting mechanisms",
      "number": "5.3",
      "page": 19,
      "pageLabel": "13",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-012-53-traceability-and-reporting-mechanisms"
    },
    {
      "level": 2,
      "title": "Standard Material Transfer Agreements",
      "number": "5.4",
      "page": 20,
      "pageLabel": "14",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-013-54-standard-material-transfer-agreements"
    },
    {
      "level": 1,
      "title": "Pandemic influenza preparedness benefit sharing system",
      "number": "6",
      "page": 21,
      "pageLabel": "15",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-015-6-pandemic-influenza-preparedness-benefit-sharin"
    },
    {
      "level": 2,
      "title": "General",
      "number": "6.0",
      "page": 21,
      "pageLabel": "15",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-014-60-general"
    },
    {
      "level": 2,
      "title": "WHO Coordination of pandemic influenza preparedness and response",
      "number": "6.1",
      "page": 21,
      "pageLabel": "15",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-016-61-who-coordination-of-pandemic-influenza-prepar"
    },
    {
      "level": 2,
      "title": "Pandemic risk assessment and risk response",
      "number": "6.2",
      "page": 22,
      "pageLabel": "16",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-017-62-pandemic-risk-assessment-and-risk-response"
    },
    {
      "level": 2,
      "title": "Provision of PIP candidate vaccine viruses",
      "number": "6.3",
      "page": 22,
      "pageLabel": "16",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-018-63-provision-of-pip-candidate-vaccine-viruses"
    },
    {
      "level": 2,
      "title": "Provision of diagnostic reagents and test kits",
      "number": "6.4",
      "page": 23,
      "pageLabel": "17",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-019-64-provision-of-diagnostic-reagents-and-test-kit"
    },
    {
      "level": 2,
      "title": "Provision of reference reagents for potency determination of vaccines",
      "number": "6.5",
      "page": 23,
      "pageLabel": "17",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-020-65-provision-of-reference-reagents-for-potency-d"
    },
    {
      "level": 2,
      "title": "Laboratory and influenza surveillance capacity building",
      "number": "6.6",
      "page": 23,
      "pageLabel": "17",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-021-66-laboratory-and-influenza-surveillance-capacit"
    },
    {
      "level": 2,
      "title": "Regulatory capacity building",
      "number": "6.7",
      "page": 24,
      "pageLabel": "18",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-022-67-regulatory-capacity-building"
    },
    {
      "level": 2,
      "title": "Antivirals stockpiles",
      "number": "6.8",
      "page": 24,
      "pageLabel": "18",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-023-68-antivirals-stockpiles"
    },
    {
      "level": 2,
      "title": "Pandemic influenza preparedness vaccine stockpile",
      "number": "6.9",
      "page": 24,
      "pageLabel": "18",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-024-69-pandemic-influenza-preparedness-vaccine-stock"
    },
    {
      "level": 2,
      "title": "Access to vaccines in the inter-pandemic period for developing countries",
      "number": "6.10",
      "page": 25,
      "pageLabel": "19",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-025-610-access-to-vaccines-in-the-inter-pandemic-per"
    },
    {
      "level": 2,
      "title": "Access to pandemic influenza vaccines",
      "number": "6.11",
      "page": 26,
      "pageLabel": "20",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-026-611-access-to-pandemic-influenza-vaccines"
    },
    {
      "level": 2,
      "title": "Tiered pricing",
      "number": "6.12",
      "page": 26,
      "pageLabel": "20",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-027-612-tiered-pricing"
    },
    {
      "level": 2,
      "title": "Technology transfer",
      "number": "6.13",
      "page": 26,
      "pageLabel": "20",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-028-613-technology-transfer"
    },
    {
      "level": 2,
      "title": "Sustainable and innovative financing mechanisms",
      "number": "6.14",
      "page": 27,
      "pageLabel": "21",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-029-614-sustainable-and-innovative-financing-mechani"
    },
    {
      "level": 1,
      "title": "Governance and review",
      "number": "7",
      "page": 29,
      "pageLabel": "23",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-030-7-governance-and-review"
    },
    {
      "level": 2,
      "title": "General",
      "number": "7.1",
      "page": 29,
      "pageLabel": "23",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-031-71-general"
    },
    {
      "level": 2,
      "title": "Advisory Group",
      "number": "7.2",
      "page": 29,
      "pageLabel": "23",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-032-72-advisory-group"
    },
    {
      "level": 2,
      "title": "Governance and review of terms of reference for WHO global influenza surveillance and response system (GISRS) laboratories",
      "number": "7.3",
      "page": 30,
      "pageLabel": "24",
      "confidence": 0.8,
      "evidence": [
        "contents",
        "body",
        "number"
      ],
      "source": "inferred",
      "section": "sec-033-73-governance-and-review-of-terms-of-reference-f"
    },
    {
      "level": 2,
      "title": "Monitoring and review of the Pandemic Influenza Preparedness Framework",
      "number": "7.4",
      "page": 31,
      "pageLabel": "25",
      "confidence": 0.55,
      "evidence": [
        "contents",
        "number"
      ],
      "source": "inferred",
      "section": null
    },
    {
      "level": 1,
      "title": "Annexes",
      "number": null,
      "page": 33,
      "pageLabel": "27",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-034-annexes"
    },
    {
      "level": 1,
      "title": "Advisory Group terms of reference",
      "number": "Annex 3",
      "page": 43,
      "pageLabel": "37",
      "confidence": 0.8,
      "evidence": [
        "contents",
        "body",
        "number"
      ],
      "source": "inferred",
      "section": "sec-035-annex-3-advisory-group-terms-of-reference"
    },
    {
      "level": 2,
      "title": "Annex 4 Guiding Principles for the development of Terms of Reference for current and potential future WHO global influenza surveillance and response system (GISRS) laboratories for H5N1 and other human pandemic influenza viruses",
      "number": "40",
      "page": 46,
      "pageLabel": "40",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-036-40-annex-4-guiding-principles-for-the-developmen"
    },
    {
      "level": 1,
      "title": "Terms of reference related to work with pandemic influenza preparedness biological materials",
      "number": "Annex 5",
      "page": 48,
      "pageLabel": "42",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-037-annex-5-terms-of-reference-related-to-work-with"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 7,
      "labelStart": "i",
      "labelEnd": "1",
      "words": 764,
      "summary": {
        "text": "The front matter of WHO's 2011 Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits. It contains the title and copyright pages and contents, and begins World Health Assembly resolution WHA64.5 of 24 May 2011, which considered the report of the Open-Ended Working Group of Member States.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pandemic influenza",
          "heading": false
        },
        {
          "term": "influenza preparedness",
          "heading": false
        },
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "influenza vaccines",
          "heading": false
        },
        {
          "term": "influenza surveillance",
          "heading": false
        },
        {
          "term": "global influenza",
          "heading": false
        },
        {
          "term": "preparedness biological",
          "heading": false
        },
        {
          "term": "preparedness framework",
          "heading": false
        }
      ],
      "extract": "Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits ii © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from",
      "extractCut": true,
      "blocks": [
        "library/10665-44796/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-wha-645-pandemic-influenza-preparedness-sharing",
      "number": null,
      "title": "WHA 64.5 Pandemic Influenza Preparedness: sharing of influenza viruses and access to vaccine sand other benefits",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 9,
      "labelStart": "1",
      "labelEnd": "3",
      "words": 245,
      "summary": {
        "text": "Completes resolution WHA64.5, in which the Health Assembly welcomes and adopts the Pandemic Influenza Preparedness Framework and asks the Director-General to implement it and report every two years through the Executive Board.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza preparedness",
          "heading": true
        },
        {
          "term": "pandemic influenza",
          "heading": true
        },
        {
          "term": "influenza viruses",
          "heading": true
        },
        {
          "term": "preparedness framework",
          "heading": false
        },
        {
          "term": "benefits",
          "heading": true
        },
        {
          "term": "sharing",
          "heading": true
        },
        {
          "term": "member states",
          "heading": false
        }
      ],
      "extract": "vaccines and other benefits;1 Acknowledging the work of the Co-Chairs and the Bureau of the Open-Ended Working Group; Welcoming the outcome of the Open-Ended Working Group of Member States on Pandemic Influenza Preparedness: sharing of influenza viruses and access to vaccines and other benefits in elaborating the Pandemic Influenza Preparedness Framework for sharing of influenza viruses and access to vaccines and",
      "extractCut": true
    },
    {
      "id": "sec-001-1-principles",
      "number": "1",
      "title": "Principles",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 12,
      "labelStart": "3",
      "labelEnd": "6",
      "words": 729,
      "summary": {
        "text": "Sets out the Framework's principles, in which Member States recall resolution WHA60.28 and note the continuing risk of a devastating influenza pandemic, especially for developing countries. They affirm the value of rapid virus sharing alongside fair access to vaccines and benefits, and recognize the need for technology transfer and financing that makes vaccines and medicines affordable for developing countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza pandemic",
          "heading": false
        },
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "influenza vaccine",
          "heading": false
        },
        {
          "term": "influenza preparedness",
          "heading": false
        },
        {
          "term": "pandemic potential",
          "heading": false
        },
        {
          "term": "human pandemic",
          "heading": false
        },
        {
          "term": "footing h5n",
          "heading": false
        },
        {
          "term": "member states",
          "heading": false
        }
      ],
      "extract": "1. Principles In relation to pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits, WHO Member States: (1) recall World Health Assembly resolution WHA60.28 on pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits; (2) note the continuing risk of an influenza pandemic with potentially devastating health, economic and",
      "extractCut": true
    },
    {
      "id": "sec-002-2-objective",
      "number": "2",
      "title": "Objective",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 13,
      "labelStart": "6",
      "labelEnd": "7",
      "words": 79,
      "summary": {
        "text": "States the Framework's objective: to improve pandemic preparedness and response by strengthening WHO's global influenza surveillance and response system, with a fair and transparent system for sharing H5N1 and other potentially pandemic viruses and for access to vaccines and other benefits.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pandemic influenza",
          "heading": false
        },
        {
          "term": "influenza preparedness",
          "heading": false
        },
        {
          "term": "objective",
          "heading": true
        }
      ],
      "extract": "2. Objective The objective of the Pandemic Influenza Preparedness Framework is to improve pandemic influenza preparedness and response, and strengthen the protection against the pandemic influenza by improving and strengthening the WHO global influenza surveillance and response system (“WHO GISRS”), with the objective of a fair, transparent, equitable, efficient, effective system for, on an equal footing: (i) the",
      "extractCut": true
    },
    {
      "id": "sec-003-3-scope",
      "number": "3",
      "title": "Scope",
      "level": 1,
      "pageStart": 13,
      "pageEnd": 14,
      "labelStart": "7",
      "labelEnd": "8",
      "words": 53,
      "summary": {
        "text": "Defines the Framework's scope as the sharing of H5N1 and other influenza viruses with human pandemic potential and related benefits, excluding seasonal influenza and other pathogens.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "scope",
          "heading": true
        },
        {
          "term": "sharing",
          "heading": false
        }
      ],
      "extract": "3. Scope 3.1 This Framework applies to the sharing of H5N1 and other influenza viruses with human pandemic potential and the sharing of benefits. 3.2 This Framework does not apply to seasonal influenza viruses or other non- influenza pathogens or biological substances that may be contained in clinical specimens shared under this Framework.",
      "extractCut": false
    },
    {
      "id": "sec-004-4-definitions-and-use-of-terms",
      "number": "4",
      "title": "Definitions and use of terms",
      "level": 1,
      "pageStart": 14,
      "pageEnd": 14,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 22,
      "summary": {
        "text": "Introduces the section defining terms used in the Framework.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "4. Definitions and use of terms For the purpose of this Framework, the following terms have the meanings assigned to them below.",
      "extractCut": false
    },
    {
      "id": "sec-005-41-pandemic-influenza-preparedness-biological-ma",
      "number": "4.1",
      "title": "Pandemic influenza preparedness biological materials or PIP biological materials",
      "level": 2,
      "pageStart": 14,
      "pageEnd": 14,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 116,
      "summary": {
        "text": "Defines 'PIP biological materials' as clinical specimens, wild-type and modified isolates of H5N1 and other potentially pandemic influenza viruses, and their extracted RNA and cDNA covering whole gene coding regions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "biological materials",
          "heading": true
        },
        {
          "term": "pip biological",
          "heading": true
        },
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "pandemic",
          "heading": true
        }
      ],
      "extract": "materials “PIP biological materials”,1 for the purposes of this Framework (and its annexed Standard Material Transfer Agreements (SMTAs) and terms of reference (TORs)) and the Influenza Virus Tracking Mechanism (IVTM), includes human clinical specimens,2 virus isolates of wild type human H5N1 and other influenza viruses with human pandemic potential; and modified viruses prepared from H5N1 and/or other influenza",
      "extractCut": true
    },
    {
      "id": "sec-006-42-other-technical-terms",
      "number": "4.2",
      "title": "Other technical terms",
      "level": 2,
      "pageStart": 14,
      "pageEnd": 16,
      "labelStart": "8",
      "labelEnd": "10",
      "words": 543,
      "summary": {
        "text": "Defines further technical terms used in the Framework, such as genetic sequences, reference reagents, candidate vaccine viruses and wild-type influenza viruses.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "wild-type influenza",
          "heading": false
        },
        {
          "term": "influenza virus",
          "heading": false
        },
        {
          "term": "influenza vaccine",
          "heading": false
        },
        {
          "term": "influenza reference",
          "heading": false
        },
        {
          "term": "who-recommended influenza",
          "heading": false
        },
        {
          "term": "means wild-type",
          "heading": false
        },
        {
          "term": "high-growth reassortant",
          "heading": false
        }
      ],
      "extract": "“Genetic sequences” means the order of nucleotides found in a molecule of DNA or RNA. They contain the genetic information that determines the biological characteristics of an organism or a virus. “Reference reagents” are biological or chemical substances or organisms and parts thereof used in diagnostic or surveillance activities. They are rigorously characterized and shown to be suitable for use as standards in",
      "extractCut": true
    },
    {
      "id": "sec-007-43-institutions-organizations-and-entities",
      "number": "4.3",
      "title": "Institutions, organizations and entities",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 17,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 374,
      "summary": {
        "text": "Defines the institutions involved, such as essential regulatory laboratories, influenza vaccine, diagnostic and drug manufacturers and the laboratories that make up WHO's global influenza surveillance and response system.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza laboratories",
          "heading": false
        },
        {
          "term": "means influenza",
          "heading": false
        },
        {
          "term": "influenza centres",
          "heading": false
        },
        {
          "term": "laboratories designated",
          "heading": false
        },
        {
          "term": "laboratories authorized",
          "heading": false
        },
        {
          "term": "influenza vaccines",
          "heading": false
        },
        {
          "term": "national influenza",
          "heading": false
        },
        {
          "term": "reference laboratories",
          "heading": false
        }
      ],
      "extract": "“Essential regulatory laboratories” means influenza laboratories designated by WHO located in, or associated with, national regulatory agencies and which have a critical role at the global level for developing, regulating and standardizing human influenza vaccines. Such laboratories participate in the WHO GISRS in accordance with their corresponding terms of reference. “Influenza vaccine, diagnostic and",
      "extractCut": true
    },
    {
      "id": "sec-008-44-other-terms",
      "number": "4.4",
      "title": "Other terms",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 18,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 252,
      "summary": {
        "text": "Defines other terms used in the Framework, including Advisory Group, affected country, least-developed country and the PIP vaccine stockpile.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "pandemic influenza",
          "heading": false
        },
        {
          "term": "influenza preparedness",
          "heading": false
        },
        {
          "term": "vaccine stockpile",
          "heading": false
        },
        {
          "term": "pip biological",
          "heading": false
        },
        {
          "term": "human pandemic",
          "heading": false
        },
        {
          "term": "pandemic potential",
          "heading": false
        },
        {
          "term": "preparedness framework",
          "heading": false
        }
      ],
      "extract": "“Advisory Group” means the Group referred to in section 7.2 of this Framework. “Affected country” means countries with laboratory confirmed cases of H5N1, or other influenza viruses with human pandemic potential. “Director-General” means the Director-General of the World Health Organization. “Least-developed country” means those countries that are periodically classified as least-developed countries by the United",
      "extractCut": true
    },
    {
      "id": "sec-009-5-pandemic-influenza-preparedness-system-for-sha",
      "number": "5",
      "title": "Pandemic influenza preparedness system for sharing of H5N1 and other influenza viruses with human pandemic potential",
      "level": 1,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 12,
      "summary": {
        "text": "A heading for the section on the system for sharing H5N1 and other potentially pandemic influenza viruses.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "for sharing of H5N1 and other influenza viruses with human pandemic potential",
      "extractCut": false
    },
    {
      "id": "sec-010-51-general",
      "number": "5.1",
      "title": "General",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 236,
      "summary": {
        "text": "Sets out that Member States should rapidly share PIP biological materials from all cases of H5N1 and other potentially pandemic influenza through their national laboratories with a WHO Collaborating Centre or H5 Reference Laboratory of their choice. It notes they may also share bilaterally if WHO laboratories receive the materials with priority.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza centres",
          "heading": false
        },
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "authorized laboratories",
          "heading": false
        },
        {
          "term": "collaborating centres",
          "heading": false
        },
        {
          "term": "pip biological",
          "heading": false
        },
        {
          "term": "biological materials",
          "heading": false
        },
        {
          "term": "national influenza",
          "heading": false
        }
      ],
      "extract": "5.1.1 Member States, through their National Influenza Centres and Other authorized laboratories, should in a rapid, systematic and timely manner provide PIP biological materials from all cases of H5N1 and other influenza viruses with human pandemic potential, as feasible, to the WHO Collaborating Centre on Influenza or WHO H5 Reference Laboratory of the originating Member State’s choice. 5.1.2 By providing PIP",
      "extractCut": true
    },
    {
      "id": "sec-011-52-genetic-sequence-data",
      "number": "5.2",
      "title": "Genetic sequence data",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 19,
      "labelStart": "12",
      "labelEnd": "13",
      "words": 148,
      "summary": {
        "text": "Calls for rapid sharing of genetic sequence data on potentially pandemic influenza viruses with originating laboratories and within GISRS, and asks the Director-General to seek advice on handling such data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "genetic sequence",
          "heading": true
        },
        {
          "term": "sequence data",
          "heading": true
        },
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "pandemic potential",
          "heading": false
        },
        {
          "term": "recognizing",
          "heading": false
        }
      ],
      "extract": "5.2.1 Genetic sequence data, and analyses arising from that data, relating to H5N1 and other influenza viruses with human pandemic potential should 13 be shared in a rapid, timely and systematic manner with the originating laboratory and among WHO GISRS laboratories. 5.2.2 Recognizing that greater transparency and access concerning influenza virus genetic sequence data is important to public health and there is a",
      "extractCut": true
    },
    {
      "id": "sec-012-53-traceability-and-reporting-mechanisms",
      "number": "5.3",
      "title": "Traceability and reporting mechanisms",
      "level": 2,
      "pageStart": 19,
      "pageEnd": 20,
      "labelStart": "13",
      "labelEnd": "14",
      "words": 220,
      "summary": {
        "text": "Commits the Director-General to set up an electronic system to track in real time the movement of PIP biological materials into, within and out of GISRS, and to give feedback to originating laboratories and countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pandemic influenza",
          "heading": false
        },
        {
          "term": "pip biological",
          "heading": false
        },
        {
          "term": "traceability mechanism",
          "heading": false
        },
        {
          "term": "biological materials",
          "heading": false
        },
        {
          "term": "director-general",
          "heading": false
        },
        {
          "term": "originating",
          "heading": false
        }
      ],
      "extract": "5.3.1 The Director-General, in consultation with the Advisory Group,1 will put in place in a timely manner a transparent traceability mechanism that uses an electronic system in order to track in real time the movement of PIP biological materials into, within, and out of the WHO GISRS. 5.3.2 To ensure that rapid, systematic and timely feedback is provided to Originating laboratories and Member States, the",
      "extractCut": true
    },
    {
      "id": "sec-013-54-standard-material-transfer-agreements",
      "number": "5.4",
      "title": "Standard Material Transfer Agreements",
      "level": 2,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "14",
      "labelEnd": "15",
      "words": 86,
      "summary": {
        "text": "States that Standard Material Transfer Agreement 1 governs transfers of PIP biological materials within GISRS, and that SMTA 2 will be used for agreements with entities outside it.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "material transfer",
          "heading": true
        },
        {
          "term": "standard material",
          "heading": true
        },
        {
          "term": "agreements",
          "heading": true
        }
      ],
      "extract": "5.4 Standard Material Transfer Agreements 5.4.1 The Standard Material Transfer Agreement 1 (SMTA 1) in Annex 1 will be used to cover all transfers of PIP biological materials within the WHO GISRS for the duration of its applicability. 5.4.2 The Director-General will, using the Standard Material Transfer Agreement 2 (SMTA 2) in Annex 2, enter into agreements with entities outside the WHO GISRS. Such agreements will",
      "extractCut": true
    },
    {
      "id": "sec-014-60-general",
      "number": "6.0",
      "title": "General",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 197,
      "summary": {
        "text": "Sets out the general aims of the PIP benefit-sharing system, to which Member States and manufacturers should contribute, covering surveillance and risk assessment, access to vaccines and supplies, and capacity building and technology transfer for receiving countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza vaccines",
          "heading": false
        },
        {
          "term": "pandemic surveillance",
          "heading": false
        },
        {
          "term": "warning information",
          "heading": false
        },
        {
          "term": "risk assessment",
          "heading": false
        },
        {
          "term": "member states",
          "heading": false
        },
        {
          "term": "health risk",
          "heading": false
        },
        {
          "term": "public health",
          "heading": false
        }
      ],
      "extract": "6.0.1 Member States should, working with the WHO Secretariat, contribute to a pandemic influenza benefit-sharing system and call upon relevant institutions, organizations, and entities, influenza vaccines, diagnostics and pharmaceutical manufacturers and public health researchers to also make appropriate contribution to this system. 6.0.2 The PIP Benefit Sharing System will operate to: (i) provide pandemic",
      "extractCut": true
    },
    {
      "id": "sec-015-6-pandemic-influenza-preparedness-benefit-sharin",
      "number": "6",
      "title": "Pandemic influenza preparedness benefit sharing system",
      "level": 1,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 19,
      "summary": {
        "text": "Notes that the benefit-sharing system includes the elements set out in the rest of the section.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "The pandemic influenza preparedness Benefit Sharing System will include the elements set out in the remainder of this part.",
      "extractCut": false
    },
    {
      "id": "sec-016-61-who-coordination-of-pandemic-influenza-prepar",
      "number": "6.1",
      "title": "WHO Coordination of pandemic influenza preparedness and response",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 94,
      "summary": {
        "text": "States that WHO will coordinate pandemic preparedness and response under the International Health Regulations (2005), with attention to fair and transparent allocation of scarce vaccines, antivirals and diagnostics according to public health risk and need.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pandemic",
          "heading": true
        },
        {
          "term": "influenza",
          "heading": true
        },
        {
          "term": "preparedness",
          "heading": true
        }
      ],
      "extract": "WHO will coordinate influenza pandemic preparedness and response in accordance with applicable International Health Regulations (2005) provisions and this 16 Framework. As regards the benefits outlined in this Framework, WHO should pay particular attention to policies and practices that promote the fair, equitable and transparent allocation of scarce medical resources (including, but not limited to, vaccines,",
      "extractCut": true
    },
    {
      "id": "sec-017-62-pandemic-risk-assessment-and-risk-response",
      "number": "6.2",
      "title": "Pandemic risk assessment and risk response",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 177,
      "summary": {
        "text": "Commits GISRS laboratories to share laboratory analysis reports with WHO and originating countries, and WHO to support countries, especially developing ones, in pandemic risk assessment and response through information and technical assistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pandemic risk",
          "heading": true
        },
        {
          "term": "risk response",
          "heading": true
        },
        {
          "term": "meaningful risk",
          "heading": false
        },
        {
          "term": "member states",
          "heading": false
        },
        {
          "term": "affected countries",
          "heading": false
        },
        {
          "term": "developing countries",
          "heading": false
        }
      ],
      "extract": "6.2.1 WHO GISRS laboratories will make available to the WHO Secretariat and the originating Member State, in a rapid, systematic and timely manner, a summary report of laboratory analyses and on request any other available information required regarding PIP biological materials to enable the affected countries and in particular, developing countries, to make an effective and meaningful risk response. 6.2.2 WHO will",
      "extractCut": true
    },
    {
      "id": "sec-018-63-provision-of-pip-candidate-vaccine-viruses",
      "number": "6.3",
      "title": "Provision of PIP candidate vaccine viruses",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 23,
      "labelStart": "16",
      "labelEnd": "17",
      "words": 86,
      "summary": {
        "text": "Sets out that WHO laboratories will provide candidate vaccine viruses on request to manufacturers without preference and at the same time to Member States' laboratories, under appropriate biosafety rules.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "candidate vaccine",
          "heading": true
        },
        {
          "term": "pip candidate",
          "heading": true
        },
        {
          "term": "vaccine viruses",
          "heading": true
        }
      ],
      "extract": "6.3.1 The Director-General will ensure that WHO Collaborating Centres on Influenza/H5 Reference Labs and Essential Regulatory Laboratories, as agreed in the terms of reference, provide PIP candidate vaccine viruses upon request: (i) to influenza vaccine manufacturers on a no preference basis; (ii) at the same time to the laboratories of originating and other Member States; (iii) to any other laboratory. 17 6.3.2 Any",
      "extractCut": true
    },
    {
      "id": "sec-019-64-provision-of-diagnostic-reagents-and-test-kit",
      "number": "6.4",
      "title": "Provision of diagnostic reagents and test kits",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 23,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 97,
      "summary": {
        "text": "Commits WHO laboratories to supply free non-commercial diagnostic reagents and test kits to national laboratories and urges diagnostic manufacturers to provide them free or at reduced cost.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "diagnostic reagents",
          "heading": true
        },
        {
          "term": "test kits",
          "heading": true
        },
        {
          "term": "influenza",
          "heading": false
        }
      ],
      "extract": "6.4.1 WHO Collaborating Centres on Influenza, WHO H5 Reference Laboratories and Essential Regulatory Laboratories, working with the WHO Secretariat, will continue to make available to National Influenza Centres and Other authorized laboratories, without charge, supplies of noncommercial diagnostic reagents and test kits for the identification and characterization of clinical specimens of influenza. 6.4.2 Influenza",
      "extractCut": true
    },
    {
      "id": "sec-020-65-provision-of-reference-reagents-for-potency-d",
      "number": "6.5",
      "title": "Provision of reference reagents for potency determination of vaccines",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 23,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 71,
      "summary": {
        "text": "Commits essential regulatory laboratories to provide reference reagents for vaccine potency testing and training in vaccine quality control to all Member States on request.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "regulatory laboratories",
          "heading": false
        },
        {
          "term": "essential regulatory",
          "heading": false
        },
        {
          "term": "vaccines",
          "heading": true
        }
      ],
      "extract": "6.5.1 Essential Regulatory Laboratories will continue to provide, upon request, reference reagents for potency determination of vaccines against H5N1 and other viruses of human pandemic potential to national regulatory laboratories and influenza vaccine manufacturers of all Member States. 6.5.2 Essential Regulatory Laboratories will continue to provide upon request, training in quality control of vaccines against",
      "extractCut": true
    },
    {
      "id": "sec-021-66-laboratory-and-influenza-surveillance-capacit",
      "number": "6.6",
      "title": "Laboratory and influenza surveillance capacity building",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 24,
      "labelStart": "17",
      "labelEnd": "18",
      "words": 86,
      "summary": {
        "text": "Urges Member States with advanced capacity to help others, especially developing countries, build laboratory and influenza surveillance capacity, including virus detection and research.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza surveillance",
          "heading": true
        },
        {
          "term": "surveillance capacity",
          "heading": true
        },
        {
          "term": "member states",
          "heading": false
        }
      ],
      "extract": "6.6.1 Upon request, Member States with advanced laboratory and influenza surveillance capacity are urged to continue to work with WHO and other Member States, particularly developing countries, to develop national laboratory and influenza surveillance capacity, including: (i) to conduct early detection, isolation and characterization of viruses; (ii) to participate in pandemic risk assessment and response; (iii) to",
      "extractCut": true
    },
    {
      "id": "sec-022-67-regulatory-capacity-building",
      "number": "6.7",
      "title": "Regulatory capacity building",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 121,
      "summary": {
        "text": "Calls on Member States with advanced regulatory capacity to help strengthen regulators in developing countries so that pandemic influenza vaccines, diagnostics and medicines can be approved rapidly, and to share information on approvals.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "regulatory capacity",
          "heading": true
        },
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "pip biological",
          "heading": false
        },
        {
          "term": "pharmaceutical products",
          "heading": false
        }
      ],
      "extract": "6.7 Regulatory capacity building 6.7.1 Upon request, Member States with advanced regulatory capacity should improve and strengthen the work that has been undertaken by Member States with WHO, particularly in developing countries, to strengthen the capacity of regulatory authorities to carry out the necessary measures for the rapid approval of safe and effective human influenza vaccines, diagnostics and",
      "extractCut": true
    },
    {
      "id": "sec-023-68-antivirals-stockpiles",
      "number": "6.8",
      "title": "Antivirals stockpiles",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 144,
      "summary": {
        "text": "Commits the Director-General to work with partners and manufacturers to maintain a WHO stockpile of antiviral medicines and to seek expert advice on its size and use.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "antiviral medicines",
          "heading": false
        },
        {
          "term": "stockpiles",
          "heading": true
        },
        {
          "term": "pandemic potential",
          "heading": false
        },
        {
          "term": "human pandemic",
          "heading": false
        }
      ],
      "extract": "6.8.1 The Director-General will continue to work with other multilateral agencies, donors, international philanthropic organizations/entities, private foundations, and other potential partners, including institutions, organizations and entities and in particular influenza vaccine, diagnostic and pharmaceutical manufacturers, to seek commitments for contributions, maintain and further develop a stockpile of antiviral",
      "extractCut": true
    },
    {
      "id": "sec-024-69-pandemic-influenza-preparedness-vaccine-stock",
      "number": "6.9",
      "title": "Pandemic influenza preparedness vaccine stockpile",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 25,
      "labelStart": "18",
      "labelEnd": "19",
      "words": 308,
      "summary": {
        "text": "Commits the Director-General to establish a WHO stockpile of vaccines for H5N1 and other potentially pandemic viruses, initially 150 million doses, with related equipment. It covers allocation according to expert guidance and plans for deploying the vaccines to affected countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vaccine stockpile",
          "heading": true
        },
        {
          "term": "pip vaccine",
          "heading": false
        },
        {
          "term": "influenza",
          "heading": true
        },
        {
          "term": "pandemic",
          "heading": true
        },
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "million doses",
          "heading": false
        },
        {
          "term": "pandemic potential",
          "heading": false
        },
        {
          "term": "human pandemic",
          "heading": false
        }
      ],
      "extract": "6.9.1 The Director-General will establish and maintain a stockpile of vaccines for H5N1 and other influenza viruses with human pandemic potential and associated equipment, including syringes, needles and applicators, consistent with expert guidance. 19 6.9.2 The WHO stockpile will initially include 150 million doses of H5N1 vaccine for use in accordance with expert guidance including the Strategic Advisory Group of",
      "extractCut": true
    },
    {
      "id": "sec-025-610-access-to-vaccines-in-the-inter-pandemic-per",
      "number": "6.10",
      "title": "Access to vaccines in the inter-pandemic period for developing countries",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 26,
      "labelStart": "19",
      "labelEnd": "20",
      "words": 125,
      "summary": {
        "text": "Urges manufacturers to reserve part of each production cycle of H5N1 and other potentially pandemic vaccines for developing countries and seeks timely access for them at tiered prices.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "influenza vaccine",
          "heading": false
        },
        {
          "term": "developing countries",
          "heading": true
        },
        {
          "term": "vaccine manufacturers",
          "heading": false
        }
      ],
      "extract": "6.10.1 Separately from measures to support the WHO PIP vaccine stockpile set out in section 6.9 above: (i) Member States should urge influenza vaccine manufacturers to set aside a portion of each production cycle of vaccines for H5N1 and other influenza viruses with human pandemic potential for stockpiling and/or use, as appropriate, by developing countries; and (ii) Member States should continue to work with each",
      "extractCut": true
    },
    {
      "id": "sec-026-611-access-to-pandemic-influenza-vaccines",
      "number": "6.11",
      "title": "Access to pandemic influenza vaccines",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 79,
      "summary": {
        "text": "Urges manufacturers to reserve part of pandemic vaccine production for developing countries and calls for an expert group to develop mechanisms for distributing vaccines by public health risk and need.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza",
          "heading": true
        },
        {
          "term": "pandemic",
          "heading": true
        },
        {
          "term": "member states",
          "heading": false
        }
      ],
      "extract": "6.11.1 Member States should urge vaccine manufacturers to set aside a portion of each production cycle of pandemic influenza vaccine for use by developing countries; and 6.11.2 The Director-General, consulting Member States and the Advisory Group, will convene an expert group to continue to develop international mechanisms, including existing ones, for the production and distribution of influenza vaccines on the",
      "extractCut": true
    },
    {
      "id": "sec-027-612-tiered-pricing",
      "number": "6.12",
      "title": "Tiered pricing",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 111,
      "summary": {
        "text": "Urges vaccine and antiviral manufacturers to apply tiered pricing that takes account of country income levels, with attention to the least developed countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza vaccine",
          "heading": false
        },
        {
          "term": "tiered",
          "heading": true
        },
        {
          "term": "antiviral manufacturers",
          "heading": false
        }
      ],
      "extract": "As a measure to improve the affordability for developing countries of pandemic influenza vaccines and vaccines for H5N1 and other influenza viruses with human pandemic potential, and antivirals, Member States should urge influenza vaccine and antiviral manufacturers individually to implement tiered pricing for these vaccines and antivirals. As part of this approach, influenza vaccine and antiviral manufacturers",
      "extractCut": true
    },
    {
      "id": "sec-028-613-technology-transfer",
      "number": "6.13",
      "title": "Technology transfer",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 27,
      "labelStart": "20",
      "labelEnd": "21",
      "words": 260,
      "summary": {
        "text": "Commits WHO to continue the Global Pandemic Influenza Action Plan to Increase Vaccine Supply, including new production facilities and transfer of technology and know-how. It urges manufacturers to support technology transfer and suggests countries consider seasonal influenza vaccination to sustain local production.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influenza vaccine",
          "heading": false
        },
        {
          "term": "seasonal influenza",
          "heading": false
        },
        {
          "term": "vaccine manufacturers",
          "heading": false
        },
        {
          "term": "transfer",
          "heading": true
        },
        {
          "term": "member states",
          "heading": false
        },
        {
          "term": "technology",
          "heading": true
        },
        {
          "term": "developing countries",
          "heading": false
        },
        {
          "term": "agreed terms",
          "heading": false
        }
      ],
      "extract": "6.13.1 The Director-General will continue to work closely with Member States and influenza vaccine manufacturers to implement the WHO Global Pandemic Influenza Action Plan to Increase Vaccine Supply, including its strategies to build new production facilities in developing and/or industrialized countries and through transfer of technology, skills and know-how. 6.13.2 Member States should urge influenza vaccine,",
      "extractCut": true
    },
    {
      "id": "sec-029-614-sustainable-and-innovative-financing-mechani",
      "number": "6.14",
      "title": "Sustainable and innovative financing mechanisms",
      "level": 2,
      "pageStart": 27,
      "pageEnd": 29,
      "labelStart": "21",
      "labelEnd": "23",
      "words": 488,
      "summary": {
        "text": "Sets out financing for the benefit-sharing system, including an annual Partnership Contribution from manufacturers that use GISRS, its use for preparedness and response and how it is managed. It also urges Member States to increase support for laboratory and surveillance capacity in developing countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pandemic influenza",
          "heading": false
        },
        {
          "term": "influenza preparedness",
          "heading": false
        },
        {
          "term": "running costs",
          "heading": false
        },
        {
          "term": "partnership contribution",
          "heading": false
        },
        {
          "term": "global pandemic",
          "heading": false
        },
        {
          "term": "advisory group",
          "heading": false
        },
        {
          "term": "member states",
          "heading": false
        },
        {
          "term": "pip benefit",
          "heading": false
        }
      ],
      "extract": "6.14.1 With a view to ensuring the sustainable financing of the PIP Benefit Sharing System, particularly for developing countries; and 6.14.2 Having regard to the desirability of all Member States and recipients of PIP biological materials contributing to the PIP Benefit Sharing System, financially or in kind, according to their capacity and over time; 6.14.3 Influenza vaccine, diagnostic and pharmaceutical",
      "extractCut": true
    },
    {
      "id": "sec-030-7-governance-and-review",
      "number": "7",
      "title": "Governance and review",
      "level": 1,
      "pageStart": 29,
      "pageEnd": 29,
      "labelStart": "23",
      "labelEnd": "23",
      "words": 4,
      "summary": {
        "text": "A heading for the section on governance and review of the Framework.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "7. Governance and review",
      "extractCut": false
    },
    {
      "id": "sec-031-71-general",
      "number": "7.1",
      "title": "General",
      "level": 2,
      "pageStart": 29,
      "pageEnd": 29,
      "labelStart": "23",
      "labelEnd": "23",
      "words": 158,
      "summary": {
        "text": "Sets out that the World Health Assembly oversees the Framework with advice from the Director-General, through an oversight mechanism that includes an independent Advisory Group of international experts.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "director-general",
          "heading": false
        },
        {
          "term": "connection",
          "heading": false
        },
        {
          "term": "overseen",
          "heading": false
        },
        {
          "term": "hereby",
          "heading": false
        },
        {
          "term": "directing",
          "heading": false
        }
      ],
      "extract": "General 7.1.1 The implementation of this Framework will be overseen by the World Health Assembly with advice from the Director-General. 7.1.2 An oversight mechanism is hereby established, which includes the World Health Assembly, the Director-General and the independent “Advisory Group”, established in connection with the Interim Statement of November 2007, and composed of international experts serving the",
      "extractCut": true
    },
    {
      "id": "sec-032-72-advisory-group",
      "number": "7.2",
      "title": "Advisory Group",
      "level": 2,
      "pageStart": 29,
      "pageEnd": 30,
      "labelStart": "23",
      "labelEnd": "24",
      "words": 355,
      "summary": {
        "text": "Describes the Advisory Group's role in monitoring and advising on the Framework without administrative or public functions, its membership and reporting, and asks for a report to the Health Assembly in 2012 on its future mandate.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "advisory group",
          "heading": true
        },
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "gisrs",
          "heading": false
        },
        {
          "term": "director-general",
          "heading": false
        },
        {
          "term": "functioning",
          "heading": false
        },
        {
          "term": "public health",
          "heading": false
        },
        {
          "term": "framework",
          "heading": false
        },
        {
          "term": "recognition",
          "heading": false
        }
      ],
      "extract": "provide evidence-based reporting, assessment and recommendations regarding the functioning of the Framework. The Advisory Group, consistent with WHO practice regarding such independent expert bodies, will advise the Director-General but will not itself engage in administrative functions, such as the recognition, or withdrawal of recognition, of technical institutions, nor will it have a public role, except as",
      "extractCut": true
    },
    {
      "id": "sec-033-73-governance-and-review-of-terms-of-reference-f",
      "number": "7.3",
      "title": "Governance and review of terms of reference for WHO global influenza surveillance and response system (GISRS) laboratories",
      "level": 2,
      "pageStart": 30,
      "pageEnd": 33,
      "labelStart": "24",
      "labelEnd": "27",
      "words": 357,
      "summary": {
        "text": "Covers terms of reference for GISRS laboratories, a review of the definition of PIP biological materials and a full review of the Framework by 2016, with proposals to the Health Assembly in 2017.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reference laboratories",
          "heading": true
        },
        {
          "term": "influenza",
          "heading": true
        },
        {
          "term": "influenza centres",
          "heading": false
        },
        {
          "term": "regulatory laboratories",
          "heading": false
        },
        {
          "term": "collaborating centres",
          "heading": false
        },
        {
          "term": "gisrs",
          "heading": true
        },
        {
          "term": "national influenza",
          "heading": false
        },
        {
          "term": "transfer agreements",
          "heading": false
        }
      ],
      "extract": "7.3.1 The terms of reference of the WHO Collaborating Centres on Influenza, WHO H5 Reference Laboratories, National Influenza Centres and Essen 25 tial Regulatory Laboratories should be developed in accordance with the guiding principles outlined in Annex 4 to this Framework. 7.3.2 The Director-General, in consultation with the Advisory Group and competent authorities in Member States, and the WHO Collaborating",
      "extractCut": true
    },
    {
      "id": "sec-034-annexes",
      "number": null,
      "title": "Annexes",
      "level": 1,
      "pageStart": 33,
      "pageEnd": 43,
      "labelStart": "27",
      "labelEnd": "37",
      "words": 2231,
      "summary": {
        "text": "Contains the Framework's annexes, beginning with Standard Material Transfer Agreement 1, which sets the terms for transferring PIP biological materials within GISRS. It then gives Standard Material Transfer Agreement 2 for transfers to recipients outside GISRS, including manufacturers' commitments to benefit sharing. The articles cover the parties, obligations, intellectual property, liability and dispute settlement, with signature blocks.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prospective recipient",
          "heading": false
        },
        {
          "term": "pandemic influenza",
          "heading": false
        },
        {
          "term": "transfer agreement",
          "heading": false
        },
        {
          "term": "influenza vaccines",
          "heading": false
        },
        {
          "term": "influenza preparedness",
          "heading": false
        },
        {
          "term": "dispute resolution",
          "heading": false
        },
        {
          "term": "biological materials",
          "heading": false
        },
        {
          "term": "influenza surveillance",
          "heading": false
        }
      ],
      "extract": "Annexes 29 Annex 1 Standard Material Transfer Agreement 1 (SMTA 1) Standard Material Transfer Agreement within the WHO global influenza surveillance and response system (GISRS ) In furtherance of the Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits (the “Framework”), this Standard Material Transfer Agreement (“Agreement” or “SMTA 1”) has been",
      "extractCut": true
    },
    {
      "id": "sec-035-annex-3-advisory-group-terms-of-reference",
      "number": "Annex 3",
      "title": "Advisory Group terms of reference",
      "level": 1,
      "pageStart": 43,
      "pageEnd": 46,
      "labelStart": "37",
      "labelEnd": "40",
      "words": 907,
      "summary": {
        "text": "Sets out the terms of reference of the Advisory Group of the Pandemic Influenza Preparedness Framework, as adopted in 2008 and amended in 2011, which is mandated to monitor, assess and report on the sharing of H5N1 and other potentially pandemic influenza viruses and on access to vaccines and other benefits. Its functions include monitoring virus sharing through the WHO Global Influenza Surveillance and Response System, the virus traceability mechanism, laboratory capacity, benefit sharing and the use of contributions, advising the Director-General and submitting an evidence-based annual report. It also specifies 18 members, three from each WHO region, serving three-year terms with annual partial renewal, confidential working procedures under WHO expert committee rules and resources provided by the Director-General.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "advisory group",
          "heading": true
        },
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "pandemic influenza",
          "heading": false
        },
        {
          "term": "influenza preparedness",
          "heading": false
        },
        {
          "term": "influenza virus",
          "heading": false
        },
        {
          "term": "non-financial contributions",
          "heading": false
        },
        {
          "term": "equitable representation",
          "heading": false
        },
        {
          "term": "human pandemic",
          "heading": false
        }
      ],
      "extract": "Terms of Reference (Adopted by the Intergovernmental Meeting at its resumed session in December 2008, as amended by the Open-Ended Working Group of Member States on Pandemic Influenza Preparedness: sharing of influenza viruses and access to vaccines and other benefits in April 2011.) 1. Background and mandate of the Advisory Group 1.1 The Interim Statement adopted by WHO Member States attending the session of the",
      "extractCut": true
    },
    {
      "id": "sec-036-40-annex-4-guiding-principles-for-the-developmen",
      "number": "40",
      "title": "Annex 4 Guiding Principles for the development of Terms of Reference for current and potential future WHO global influenza surveillance and response system (GISRS) laboratories for H5N1 and other human pandemic influenza viruses",
      "level": 2,
      "pageStart": 46,
      "pageEnd": 48,
      "labelStart": "40",
      "labelEnd": "42",
      "words": 472,
      "summary": {
        "text": "Annex 4 of the PIP Framework sets out ten guiding principles for drafting the terms of reference of WHO Global Influenza Surveillance and Response System laboratories working with H5N1 and other potentially pandemic viruses, such as consistency with the Framework and the Standard Material Transfer Agreement, WHO coordination, timely reporting and capacity-building support for Member States. Other principles cover support for vaccine and diagnostic development, involving scientists from submitting laboratories in research, rapid sharing of PIP biological materials using the traceability mechanism, submitting gene sequences to public databases and crediting originating laboratories.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gisrs laboratories",
          "heading": true
        },
        {
          "term": "pandemic influenza",
          "heading": true
        },
        {
          "term": "influenza viruses",
          "heading": true
        },
        {
          "term": "influenza surveillance",
          "heading": true
        },
        {
          "term": "global influenza",
          "heading": true
        },
        {
          "term": "human pandemic",
          "heading": true
        },
        {
          "term": "guiding principles",
          "heading": true
        },
        {
          "term": "transfer agreement",
          "heading": false
        }
      ],
      "extract": "Guiding Principles for the development of Terms of Reference for current and potential future WHO global influenza surveillance and response system (GISRS) laboratories for H5N1 and other human pandemic influenza viruses The specific roles, responsibilities and activities conducted by the different WHO global influenza surveillance and response system (GISRS) laboratories can differ depending on whether they are a",
      "extractCut": true
    },
    {
      "id": "sec-037-annex-5-terms-of-reference-related-to-work-with",
      "number": "Annex 5",
      "title": "Terms of reference related to work with pandemic influenza preparedness biological materials",
      "level": 1,
      "pageStart": 48,
      "pageEnd": 68,
      "labelStart": "42",
      "labelEnd": "62",
      "words": 6050,
      "summary": {
        "text": "Annex 5 sets out the terms of reference for work with PIP biological materials by the four types of GISRS institutions: National Influenza Centres, WHO Collaborating Centres, H5 Reference Laboratories and essential regulatory laboratories. For each it describes functions such as collecting and sharing specimens and viruses, characterizing them, developing candidate vaccine viruses and reference reagents, and supporting risk assessment. It also covers biosafety, publication and recognition of originating laboratories. The annex ends with the ISBN and WHO contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pandemic influenza",
          "heading": true
        },
        {
          "term": "influenza preparedness",
          "heading": true
        },
        {
          "term": "preparedness biological",
          "heading": true
        },
        {
          "term": "biological materials",
          "heading": true
        },
        {
          "term": "influenza viruses",
          "heading": false
        },
        {
          "term": "gisrs laboratories",
          "heading": false
        },
        {
          "term": "candidate influenza",
          "heading": false
        },
        {
          "term": "influenza centres",
          "heading": false
        }
      ],
      "extract": "Influenza Preparedness biological materials Background The WHO global influenza surveillance and response system (GISRS) serves as a global alert mechanism for the emergence of influenza viruses with important features, including those with pandemic potential. For activities related to pandemic influenza, the WHO GISRS includes four complementary categories of institutions and laboratories: National Influenza",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 1,
        "items": [
          "Monitoring and review of the Pandemic Influenza Preparedness Framework"
        ]
      },
      "found_not_listed": {
        "count": 8,
        "items": [
          "7.3 Governance and review of terms of reference for WHO GISRS Laboratories",
          "7.4 Monitoring and review of the Framework",
          "1 Background and mandate of the Advisory Group",
          "2 Functions of the Advisory Group",
          "3 Nomination of members",
          "4 Working procedures",
          "5 Resources for implementation",
          "20 Avenue Appia 1211 Geneva 27 Switzerland"
        ]
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 3,
      "items": [
        "p4: pdf-labels iv, printed ii",
        "p5: pdf-labels v, printed iii",
        "p6: pdf-labels vi, printed iv"
      ]
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "influenza pandemic",
      "heading": true
    },
    {
      "term": "influenza viruses",
      "heading": true
    },
    {
      "term": "gisrs influenza",
      "heading": true
    },
    {
      "term": "influenza laboratories",
      "heading": true
    },
    {
      "term": "influenza vaccines",
      "heading": true
    },
    {
      "term": "h5n influenza",
      "heading": true
    },
    {
      "term": "influenza preparedness",
      "heading": true
    },
    {
      "term": "influenza reference",
      "heading": true
    },
    {
      "term": "influenza centres",
      "heading": false
    },
    {
      "term": "human influenza",
      "heading": true
    },
    {
      "term": "influenza virus",
      "heading": false
    },
    {
      "term": "influenza surveillance",
      "heading": true
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "iii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 7,
      "label": "1",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "2",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 9,
      "label": "3",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 10,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "6",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 13,
      "label": "7",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 14,
      "label": "8",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 15,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "10",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 17,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 18,
      "label": "12",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 19,
      "label": "13",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "14",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 21,
      "label": "15",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "16",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "17",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 24,
      "label": "18",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 25,
      "label": "19",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 26,
      "label": "20",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 27,
      "label": "21",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 28,
      "label": "22",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "23",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 30,
      "label": "24",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "26",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "27",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 34,
      "label": "28",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "30",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "31",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "32",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "34",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 41,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "36",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "37",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 44,
      "label": "38",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 45,
      "label": "39",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 46,
      "label": "40",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 47,
      "label": "41",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 48,
      "label": "42",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 49,
      "label": "43",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 50,
      "label": "44",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 51,
      "label": "45",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 52,
      "label": "46",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "47",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 54,
      "label": "48",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 55,
      "label": "49",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 56,
      "label": "50",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 57,
      "label": "51",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 58,
      "label": "52",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 59,
      "label": "53",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 60,
      "label": "54",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 61,
      "label": "55",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 62,
      "label": "56",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 63,
      "label": "57",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 64,
      "label": "58",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 65,
      "label": "59",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 66,
      "label": "60",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 67,
      "label": "61",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 68,
      "label": "62",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [],
  "images": [
    {
      "id": "img-p068-1",
      "file": "images/img-p068-1.webp",
      "page": 68,
      "narratives": {
        "en": "ISBN barcode with the number 9789241503082.",
        "ar": "رمز شريطي للرقم الدولي المعياري للكتاب (ISBN) يحمل الرقم 9789241503082.",
        "zh": "国际标准书号（ISBN）条形码，编号为9789241503082。",
        "es": "Código de barras del ISBN con el número 9789241503082.",
        "fr": "Code-barres ISBN portant le numéro 9789241503082.",
        "ru": "Штрихкод ISBN с номером 9789241503082."
      },
      "state": "draft"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 39,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 39,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 1
    },
    {
      "kind": "tables",
      "state": "not-extracted"
    },
    {
      "kind": "references",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "found",
      "count": 17
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 39,
      "note": "39 of 39 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-44796"
  }
}
